

Company Overview

Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of important new drug products for growing markets. Citius is currently advancing three proprietary product candidates: Mino-Lok[®], CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Citius believes the markets for its products are large and underserved by the current standard of care.

Citius Reaches First Interim Analysis Milestone for Mino-Lok[®] Pivotal Trial

Oct 7 2019, 8:30 AM EDT

Citius Provides Update on Activities From IDWeek 2019

Oct 3 2019, 7:00 AM EDT

Citius Announces Closing of \$7.0 Million Underwritten Offering Priced At-the-Market

Sep 27 2019, 11:28 AM EDT

Stock Overview

| | |
|---------------|-----------------|
| Symbol | CTXR |
| Exchange | Nasdaq |
| Market Cap | 17.59m |
| Last Price | \$0.61 |
| 52-Week Range | \$0.42 - \$1.79 |

10/11/2019 03:59 PM EDT

Investor Relations

| |
|--------------------------|
| Andrew Scott |
| VP of Investor Relations |
| T: 908-967-6677 ext. 105 |

Management Team

Myron Holubiak

President, Chief Executive Officer and Director

Jaime Bartushak

Chief Financial Officer and Principal Financial Officer

Gary F. Talarico

Executive Vice President, Operations

Citius Pharmaceuticals, Inc.

11 Commerce Drive
First Floor
Cranford, NJ 07016

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.